# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0000886163-19-000065
Filing Date
2019-04-24
Accepted
2019-04-23 18:14:46
Documents
4
Effectiveness Date
2019-04-24

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | proxynotice2019.htm | DEFA14A | 18334
2 |  | ligandlogo41719a02.jpg | GRAPHIC | 12141
3 |  | noticecard1of2.jpg | GRAPHIC | 355020
4 |  | noticecard2of2.jpg | GRAPHIC | 279082
| Complete submission text file | 0000886163-19-000065.txt |  | 893318

Mailing Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121
Business Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121 858-550-7500
LIGAND PHARMACEUTICALS INC (Filer) CIK: 0000886163 (see all company filings)

EIN.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-33093 | Film No.: 19762335
SIC: 2834 Pharmaceutical Preparations